Olusola Olalekan Elekofehinti, Ifeoluwa Rachael Adetoyi, Hannah Oluwaseun Popoola, Folasade Oluwatobiloba Ayodeji, Foluso Adeola Taiwo, Moses Orimoloye Akinjiyan, Omowunmi Funmilayo Koledoye, Opeyemi Iwaloye, Abayomi Emmanuel Adegboyega
UNLABELLED: A tyrosine kinase receptor known as epidermal growth factor receptor (EGFR) is one of the main tumour markers in many cancer types and also plays a crucial role in cell proliferation, differentiation, angiogenesis, and apoptosis, which is a result of the auto-phosphorylations (kinase activity enhancement) that trigger signals involved in different cellular processes. Due to the discovery that non-small cell lung cancer (NSCLC) is a cause of this kinase activity enhancement, so far, several inhibitors have been tested against EGFR, but the side effects of these inhibitors necessitate an urgent measure to come up with an inhibitor that will be more specific to the cancer cells and not affect self-cells...
2024: In Silico Pharmacology